Pfizer achieves primary endpoint with phase 3B top-line results of Genotropin in very young children born small for gestational age (Business Wire, 26 March 2014)

Long-term productivity higher in university spin-offs than in other companies (EurekAlert, 25 March 2014)

Exelixis gains European Cometriq nod with note about low response in non-RET mutated MTC patients (Pharmacogenomics Reporter, 25 March 2014)

26 Mar 2014

The European Commission has approved Cometriq (cabozantinib) as a treatment for medullary thyroid cancer (MTC) patients.

Share this story

Top stories

Call for nominations for Awards Committee Chair
30 Oct 2024

James M Tanner Award - 2025 nominations open
30 Oct 2024

Would you like to host the BSPED annual meeting?
21 Oct 2024

Most read